Fatigue is expected to be the most prevalent symptom in patients with ILD (IPF and sarcoidosis), next to dyspnoea. Frequency of moderate to severe fatigue in patients with ILD is unknown. In addition, possible correlates of fatigue, including age,…
ID
Bron
Verkorte titel
Aandoening
Fatigue, ILD, IPF, Sarcoidosis
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Fatigue, measured by the Cis-Fat (Attachment A), is the primary outcome. The Cis-Fat consists of eight items, scored on a 7-point Likert scale. The range of scores is from 8 (normal fatigue) to 56 (most severe fatigue), with a higher score indicating a higher level of fatigue. Scores ¡Ü26 points indicate normal fatigue, scores 27 to 35 indicate moderate fatigue and scores ¡Ý35 indicate severe fatigue
Achtergrond van het onderzoek
Patients with interstitial lung disease (ILD; in this study limited to idiopathic pulmonary fibrosis or sarcoidosis) frequently report fatigue. Fatigue is expected to be the most prevalent symptom in patients with ILD, next to dyspnoea. This study is to determine the frequency of moderate to severe fatigue in patients with ILD (IPF and sarcoidosis)
Doel van het onderzoek
Fatigue is expected to be the most prevalent symptom in patients with ILD (IPF and sarcoidosis), next to dyspnoea. Frequency of moderate to severe fatigue in patients with ILD is unknown. In addition, possible correlates of fatigue, including age, gender, body mass index, the degree of lung function impairment, dyspnoea, health status, symptoms of anxiety/depression, grief, sleepiness and catastrophizing thoughts will be evaluated.
Onderzoeksopzet
Not applicable
Onderzoeksproduct en/of interventie
A cross-sectional questionnaire study. In the current study no product, medicinal product, food product or medical device will be investigated.
Publiek
3501 AA
Ada E.M. Bloem
Heidelberglaan 7
3584 CS
Utrecht
The Netherlands
06 38763295
aadje.bloem@hu.nl | www.hu.nl
Wetenschappelijk
3501 AA
Ada E.M. Bloem
Heidelberglaan 7
3584 CS
Utrecht
The Netherlands
06 38763295
aadje.bloem@hu.nl | www.hu.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Clinically stable diagnosed pulmonary fibrosis or sarcoidosis (no exacerbation/hospitalization <4 weeks) from the outpatient clinic of the Department of Respiratory Medicine (Zuyderland Heerlen or Sittard)
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
A potential subject who meets any of the following criteria will be excluded from participation in this study:
1. Lack of sufficient understanding of the Dutch language;
2. Unable to complete questionnaires because of cognitive impairment;
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL6945 |
| NTR-old | NTR7201 |
| Ander register | : METCZ20180027 |